|
1
|
Kirschbrown WP, Wynne C, Kågedal M, Wada
R, Li H, Wang B, Nijem I, Crnjevic TB, Gasser H, Heeson S, et al:
Development of a subcutaneous fixed-dose combination of pertuzumab
and trastuzumab: Results from the phase Ib dose-finding study. J
Clin Pharmacol. 59:702–716. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Swain SM, Miles D, Kim SB, Im YH, Im SA,
Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, et al:
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic
breast cancer (CLEOPATRA): End-of-study results from a
double-blind, randomised, placebo-controlled, phase 3 study. Lancet
Oncol. 21:519–530. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
DuMond B, Patel V, Gross A, Fung A and
Weber S: Fixed-dose combination of pertuzumab and trastuzumab for
subcutaneous injection in patients with HER2-positive breast
cancer: A multidisciplinary approach. J Oncol Pharm Pract.
27:1214–1221. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
O'Shaughnessy J, Sousa S, Cruz J,
Fallowfield L, Auvinen P, Pulido C, Cvetanovic A, Wilks S, Ribeiro
L, Burotto M, et al: Preference for the fixed-dose combination of
pertuzumab and trastuzumab for subcutaneous injection in patients
with HER2-positive early breast cancer (PHranceSCa): A randomised,
open-label phase II study. Eur J Cancer. 152:223–232.
2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Tan AR, Im SA, Mattar A, Colomer R,
Stroyakovskii D, Nowecki Z, De Laurentiis M, Pierga JY, Jung KH,
Schem C, et al: Fixed-dose combination of pertuzumab and
trastuzumab for subcutaneous injection plus chemotherapy in
HER2-positive early breast cancer (FeDeriCa): A randomised,
open-label, multicentre, non-inferiority, phase 3 study. Lancet
Oncol. 22:85–97. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sakaeda M, Kotani N, Yoneya T, Zheng Y and
Habara Y: [Pharmacological properties and clinical development
overview of pertuzumab (genetical recombination), trastuzumab
(genetical recombination) and vorhyaluronidase alfa (genetical
recombination) (PHESGO(®) combination for subcutaneous injection
MA, IN)]. Nihon Yakurigaku Zasshi. 159:241–253. 2024.PubMed/NCBI View Article : Google Scholar : (In Japanese).
|
|
7
|
Thompson LM, Eckmann K, Boster BL, Hess
KR, Michaud LB, Esteva FJ, Hortobágyi GN and Barnett CM: Incidence,
risk factors, and management of infusion-related reactions in
breast cancer patients receiving trastuzumab. Oncologist.
19:228–234. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tabuchi Y, Tsujimoto M, Yamamoto K,
Shimizu R, Kosaka T, Sakaguchi K, Dobuchi N, Nishiguchi K and
Shikata K: Risk factors for infusion reactions in patients with
breast cancer administered trastuzumab therapy. Biol Pharm Bull.
46:964–968. 2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tatsuta R, Sumimoto T, Nakahara R, Tanaka
R and Itoh H: Comparison of treatment safety between brand-name
product and biosimilar of trastuzumab. Gan To Kagaku Ryoho.
48:945–949. 2021.PubMed/NCBI(In Japanese).
|
|
10
|
Baselga J, Cortés J, Kim SB, Im SA, Hegg
R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al:
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast
cancer. N Engl J Med. 366:109–119. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
von Minckwitz G, Procter M, de Azambuja E,
Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N,
Clark E, et al: Adjuvant pertuzumab and trastuzumab in early
HER2-positive breast cancer. N Engl J Med. 377:122–131.
2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Swain SM, Tan AR, Gianni L, Kuemmel S,
Dang CT, Schneeweiss A, O'Shaughnessy J, Liu H, Aguila C, Heeson S,
et al: Incidence and severity of anaphylaxis and hypersensitivity
in trials of intravenous pertuzumab plus trastuzumab or the
fixed-dose combination of pertuzumab and trastuzumab for
subcutaneous injection for HER2-positive breast cancer. Eur J
Cancer. 178:70–81. 2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Stebbing J, Baranau Y, Baryash V, Manikhas
A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskii
D, Pikiel J, et al: CT-P6 compared with reference trastuzumab for
HER2-positive breast cancer: A randomised, double-blind,
active-controlled, phase 3 equivalence trial. Lancet Oncol.
18:917–928. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Tokunaga M, Watanabe S and Nakane N:
Survey on outpatient's waiting time and satisfaction level. J Jpn
Soc Health Care Manag. 7:324–328. 2006.
|
|
15
|
Toga-Sato S, Tosaki T, Kondo M, Tsunekawa
S, Kato Y, Nakamura J and Kamiya H: Impact of actual waiting time
and perceived waiting time on treatment satisfaction in patients
receiving outpatient diabetes care. Diabetol Int. 12:293–300.
2021.PubMed/NCBI View Article : Google Scholar
|
